Literature DB >> 21727292

Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study.

Agnes Dechartres1, Isabelle Boutron, Ludovic Trinquart, Pierre Charles, Philippe Ravaud.   

Abstract

BACKGROUND: A recent study suggested that results of single-center trials are frequently contradicted when similar trials are performed in multicenter settings.
PURPOSE: To perform a meta-epidemiologic study to evaluate whether estimates of treatment effect differ between single-center and multicenter randomized, controlled trials (RCTs). DATA SOURCES: MEDLINE was searched via PubMed for meta-analyses of RCTs with binary outcomes that were published between August 2008 and January 2009 and in the first 6 months of 2010 in the 10 leading journals of each medical specialty. One issue of the Cochrane Database of Systematic Reviews was also searched. STUDY SELECTION: All individual RCTs included in the meta-analyses were selected. DATA EXTRACTION: Data were extracted and their quality was assessed by use of the risk of bias tool of the Cochrane Collaboration. DATA SYNTHESIS: The primary outcome was the ratio of odds ratios (ROR), used to quantify the difference in estimated intervention effect between single-center and multicenter RCTs. An ROR less than 1 would indicate larger estimates of the intervention effect in single-center trials. Sensitivity analyses were performed with adjustment for sample size, risk of bias within RCTs, and variance of the log odds ratio to take publication bias into account. Forty-eight meta-analyses were selected, including 421 RCTs (223 were single-center and 198 were multicenter). Single-center RCTs showed a larger intervention effect than did multicenter RCTs (combined ROR, 0.73 [95% CI, 0.64 to 0.83]), with low heterogeneity across individual meta-analyses (I(2) = 12.0%; P = 0.24). Adjustment for sample size yielded consistent results (ROR, 0.85 [CI, 0.74 to 0.97]), as did adjustment for risk of bias within RCTs, such as allocation concealment (ROR, 0.76 [CI, 0.67 to 0.86]), and variance of log odds ratio (ROR, 0.83 [CI, 0.72 to 0.96]). LIMITATION: Despite sensitivity analyses, meta-confounding cannot be fully excluded.
CONCLUSION: Single-center RCTs showed larger treatment effects than did multicenter RCTs, a finding that was consistent in all sensitivity analyses. These results suggest that this item should be considered when the results of RCTs and meta-analyses are interpreted. PRIMARY FUNDING SOURCE: Academic grant Recherche sur la Recherche from the Délégation Interrégionale à la Recherche Clinique (DIRC), Ile de France, Assistance Publique-Hôpitaux de Paris (APHP).

Entities:  

Mesh:

Year:  2011        PMID: 21727292     DOI: 10.7326/0003-4819-155-1-201107050-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  75 in total

1.  Team Learning for Healthcare Quality Improvement.

Authors:  Narine Manukyan; Margaret J Eppstein; Jeffrey D Horbar
Journal:  IEEE Access       Date:  2013-08-28       Impact factor: 3.367

Review 2.  Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*.

Authors:  Elizabeth K Stevenson; Amanda R Rubenstein; Gregory T Radin; Renda Soylemez Wiener; Allan J Walkey
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

3.  Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Shaohua Cui; Liwen Xiong; Yuqing Lou; Huangping Shi; Aiqin Gu; Yizhuo Zhao; Tianqing Chu; Huimin Wang; Wei Zhang; Lili Dong; Liyan Jiang
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

4.  A revival for immunoglobulin therapy in septic shock?

Authors:  Julien Textoris; Thierry Calandra; Frédéric Pène
Journal:  Intensive Care Med       Date:  2014-10-30       Impact factor: 17.440

Review 5.  The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease.

Authors:  James D Lewis; Lindsey Albenberg; Dale Lee; Mario Kratz; Klaus Gottlieb; Walter Reinisch
Journal:  Inflamm Bowel Dis       Date:  2017-02       Impact factor: 5.325

Review 6.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

7.  Tunably Rugged Landscapes With Known Maximum and Minimum.

Authors:  Narine Manukyan; Margaret J Eppstein; Jeffrey S Buzas
Journal:  IEEE Trans Evol Comput       Date:  2015-07-09       Impact factor: 11.554

Review 8.  [Urolithiasis guidelines: retrospective view and perspectives].

Authors:  C Türk
Journal:  Urologe A       Date:  2016-10       Impact factor: 0.639

Review 9.  Medical expulsive therapy for ureteral stones: where do we go from here?

Authors:  Bhaskar K Somani; Omar Aboumarzouk; Olivier Traxer; Joyce Baard; Guido Kamphuis; Jean de la Rosette
Journal:  Nat Rev Urol       Date:  2016-08-02       Impact factor: 14.432

10.  Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.

Authors:  A Avilés; N Neri; J Huerta-Guzmán; M J Nambo
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.